California Hemp Regulation: Laws, Licensing, and Compliance Guide

Executive Summary

California's hemp regulation framework has become one of the most contentious cannabis policy battlegrounds in the United States, with a 2026 law sparking fierce debate over patient access to therapeutic hemp products. The state's attempt to regulate hemp-derived cannabinoids has pitted consumer advocates and small businesses against lawmakers who argue the regulations protect public health. At the center of the controversy are intoxicating hemp products containing delta-8 THC, THCA, and other cannabinoids that emerged in legal gray areas following the 2018 Farm Bill. California's regulatory approach affects approximately 39 million residents, thousands of hemp businesses, and a market estimated at over $500 million annually. The conflict highlights fundamental tensions between federal hemp law under the Agricultural Improvement Act of 2018 and state cannabis regulatory authority, with implications extending far beyond California's borders as other states watch closely to craft their own hemp policies.

Why This Matters

California's hemp regulations directly impact patient access, business viability, and the legal status of an entire category of cannabis products used by hundreds of thousands of consumers. The stakes are substantial across multiple stakeholder groups. For patients and consumers, particularly those who cannot afford or access California's regulated cannabis market, hemp-derived products have provided an affordable alternative for managing pain, anxiety, insomnia, and other conditions. Many of these consumers lack medical cannabis recommendations or live in jurisdictions where adult-use dispensaries are prohibited by local ordinance. For businesses, California's hemp industry encompasses an estimated 2,000 to 3,000 retail locations, manufacturing facilities, and distribution operations that emerged after 2018. These range from gas stations and convenience stores selling hemp products to dedicated wellness shops and online retailers. The regulatory changes threaten the business models of companies that invested millions in infrastructure, product development, and inventory. From a public health perspective, state regulators and lawmakers cite concerns about unregulated intoxicating products reaching minors, lack of testing standards, and products with potency levels rivaling or exceeding regulated cannabis. The California Department of Public Health reported a 340% increase in calls to poison control centers regarding hemp-derived cannabinoid products between 2021 and 2025. The economic impact extends to California's regulated cannabis industry, where licensed operators argue that untaxed, lightly regulated hemp products create unfair competition. Licensed cannabis businesses pay effective tax rates exceeding 30% when combining state excise taxes, local taxes, and federal 280E restrictions, while hemp retailers historically operated with minimal regulatory burden.

Background and History

California's hemp regulation saga began with the 2018 Farm Bill's legalization of hemp, creating an unintended legal pathway for intoxicating cannabinoid products that existed outside the state's carefully constructed cannabis framework.

The 2018 Farm Bill Foundation

The Agricultural Improvement Act of 2018, signed into law on December 20, 2018, removed hemp—defined as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis—from the Controlled Substances Act's Schedule I classification. This federal legislation, championed by Senate Majority Leader Mitch McConnell, was intended to support American farmers growing industrial hemp for fiber, grain, and CBD extraction. The 0.3% threshold, based on a 1976 taxonomic paper by Canadian researchers Ernest Small and Arthur Cronquist, was never intended as a bright-line distinction between intoxicating and non-intoxicating cannabis. Nevertheless, it became federal law, creating what industry observers would later call "the biggest loophole in cannabis policy history."

California's Initial Hemp Response (2019-2021)

California moved quickly to establish a hemp program following federal legalization. Assembly Bill 228, signed by Governor Gavin Newsom in October 2019, established the California Department of Food and Agriculture as the lead hemp regulatory agency and created a framework for hemp cultivation. The law explicitly prohibited adding hemp-derived CBD to food products pending FDA guidance—a prohibition that would prove largely unenforceable. However, AB 228 did not anticipate the wave of innovation that would follow. Chemists and entrepreneurs discovered that hemp-derived CBD could be converted through isomerization into delta-8 THC, a psychoactive cannabinoid that occurs naturally in cannabis in trace amounts. By 2020, delta-8 THC products flooded California's convenience stores, smoke shops, and online retailers. The California Department of Public Health issued guidance in July 2021 stating that delta-8 THC products were not legal hemp products, but enforcement proved difficult. District attorneys in most counties lacked resources or interest in prosecuting hemp retailers, and the products' quasi-legal status created confusion among law enforcement.

The THCA Phenomenon (2022-2024)

As some states moved to ban delta-8 THC, the hemp industry pivoted to THCA—tetrahydrocannabinolic acid, the non-intoxicating precursor to delta-9 THC found in raw cannabis. Because THCA converts to delta-9 THC only when heated (decarboxylated), and because the Farm Bill's 0.3% limit applies to delta-9 THC specifically, cultivators could grow cannabis plants with THCA levels of 20% or higher while maintaining delta-9 THC below 0.3% in the raw plant material. By 2023, California hemp retailers openly sold THCA flower that was functionally identical to products in licensed dispensaries. Consumers could purchase ounces of high-THCA hemp flower for $50 to $100, compared to $200 to $300 for equivalent products from licensed retailers. The price differential reflected the absence of cultivation taxes, testing requirements, and the regulatory compliance costs that burdened licensed operators. Licensed cannabis businesses, represented by the California Cannabis Industry Association, lobbied intensively for regulatory action. The CCIA argued that the hemp loophole undermined Proposition 64, the 2016 ballot initiative that legalized adult-use cannabis and promised tax revenue for public programs.

Assembly Bill 45 and the 2024 Legislative Session

In January 2024, Assemblymember Jacqui Irwin introduced Assembly Bill 45, proposing comprehensive hemp regulation. The bill would prohibit the sale of any hemp product containing "detectable amounts of tetrahydrocannabinol" intended for human consumption, effectively banning intoxicating hemp products. AB 45 moved through the legislative process with support from the California Department of Public Health, the California Cannabis Industry Association, and law enforcement organizations. Opposition came from hemp industry groups, consumer advocates, and civil liberties organizations who argued the bill would criminalize products used by vulnerable populations. The bill passed the Assembly in May 2024 with a 52-18 vote and cleared the Senate in August 2024 by a 28-10 margin. Governor Newsom signed AB 45 into law on September 24, 2024, with an implementation date of January 1, 2025, later extended to July 1, 2025, to allow for regulatory development.

Regulatory Implementation and Industry Response (2025-2026)

The California Department of Public Health published emergency regulations in March 2025, establishing testing requirements, labeling standards, and enforcement mechanisms. The regulations defined "intoxicating hemp products" as those containing more than 0.5 mg of total THC per serving or 2.5 mg per package for ingestible products, and prohibited smokable hemp flower with detectable THC. Hemp businesses filed multiple lawsuits challenging AB 45 and the implementing regulations. In Hemp Industry Association v. California Department of Public Health, filed in Sacramento County Superior Court in April 2025, plaintiffs argued the regulations violated the Commerce Clause by discriminating against interstate commerce and exceeded the state's authority under the Farm Bill's federal preemption provisions. As the July 1, 2025 implementation date approached, many retailers cleared inventory, while others announced they would continue operations and challenge enforcement actions. The regulatory uncertainty created chaos in the supply chain, with distributors refusing to ship products to California and payment processors terminating merchant accounts.

The 2026 Amendments and Current Controversy

In response to ongoing confusion and enforcement challenges, the California Legislature passed Senate Bill 1223 in June 2026, signed by Governor Newsom on July 1, 2026. SB 1223 tightened definitions, increased penalties for violations, and allocated $15 million for enforcement activities. The July 2026 Sacramento Bee article that triggered renewed attention to this issue reported on advocates' claims that SB 1223 effectively eliminated access to therapeutic hemp products for vulnerable populations. Patient advocates interviewed by the Bee described individuals who relied on affordable hemp-derived CBD and minor cannabinoid products for chronic pain, PTSD, and other conditions but could not afford licensed dispensary prices or lacked access to medical cannabis recommendations. Lawmakers quoted in the article, including Assemblymember Irwin and Senator Bill Dodd, disputed these characterizations, arguing that the regulations preserve access to non-intoxicating CBD products while eliminating dangerous, unregulated intoxicating products marketed to minors.

Key Players

California Department of Public Health

The CDPH serves as the primary regulatory agency for hemp-derived cannabinoid products under AB 45 and SB 1223. The department's Manufactured Cannabis Safety Branch, originally established to oversee licensed cannabis products, expanded its mandate to include hemp enforcement. CDPH Director Tomás Aragón has publicly supported the regulations, citing public health concerns about unregulated intoxicating products.

California Department of Food and Agriculture

CDFA maintains authority over hemp cultivation under the state's USDA-approved hemp plan. The department's Industrial Hemp Program, established in 2020, registered approximately 15,000 acres of hemp cultivation in California as of 2025. CDFA's role focuses on agricultural production rather than finished consumer products, creating a regulatory split that has complicated enforcement.

California Cannabis Industry Association

The CCIA, representing licensed cannabis businesses, has been the most vocal supporter of strict hemp regulations. The trade association argues that unregulated hemp products undermine the legal cannabis market and deprive the state of tax revenue. CCIA lobbyists worked closely with legislative staff on AB 45 and SB 1223, providing technical expertise and political support.

U.S. Hemp Roundtable

This national trade association represents hemp farmers, processors, and retailers. The organization has advocated for federal THC limits that would preserve the hemp industry while addressing state concerns about intoxicating products. The Roundtable supported a 0.3% total THC limit (including THCA) that would effectively prohibit high-potency hemp flower while preserving CBD and minor cannabinoid products.

California Hemp Association

A state-level trade group representing California hemp businesses, the CHA has opposed AB 45 and SB 1223 as overly restrictive. The association proposed alternative regulatory frameworks that would establish testing, labeling, and age verification requirements without prohibiting product categories entirely.

Patient Advocacy Groups

Organizations including Americans for Safe Access, the California chapter of NORML, and various patient rights groups have opposed the hemp regulations. These advocates argue that the laws disproportionately harm low-income patients, communities of color, and rural residents who lack access to licensed dispensaries.

Legislative Champions

Assemblymember Jacqui Irwin (D-Thousand Oaks), author of AB 45, has positioned herself as a leading voice for hemp regulation. Senator Bill Dodd (D-Napa), who chairs the Senate Governmental Organization Committee overseeing cannabis policy, authored SB 1223. Both legislators have emphasized child safety and public health in their advocacy for strict hemp regulations.

Legal and Regulatory Framework

California's hemp regulations exist at the intersection of federal agricultural law, state cannabis policy, and constitutional commerce clause principles, creating a complex legal landscape with unresolved tensions.

Federal Framework

The Agricultural Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., establishes the federal definition of hemp and removes it from the Controlled Substances Act. Section 297D of the Farm Bill preserves state authority to regulate hemp production and prohibit hemp entirely, but the scope of this state authority remains contested. The Farm Bill requires states to submit hemp plans to the USDA for approval. California's plan, approved in December 2020, governs cultivation practices, THC testing protocols, and disposal of non-compliant plants. However, the plan does not address finished consumer products, creating a regulatory gap. The Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., grants the FDA authority over food, drugs, and dietary supplements. The FDA has maintained that CBD cannot be added to food or marketed as a dietary supplement without agency approval, but has largely declined to enforce this position, creating de facto tolerance for CBD products.

California Statutory Framework

Assembly Bill 45, codified as California Health and Safety Code § 11018.5, defines "industrial hemp" consistent with federal law but prohibits manufacturing, distributing, or selling any industrial hemp product containing "detectable amounts of tetrahydrocannabinol" for human or animal consumption. The statute includes exceptions for trace amounts resulting from naturally occurring THC in compliant hemp. Senate Bill 1223 amended Health and Safety Code § 11018.5 to clarify that "tetrahydrocannabinol" includes all THC isomers and their precursors, explicitly encompassing THCA, delta-8 THC, delta-10 THC, and other variants. The law establishes civil penalties up to $10,000 per violation and authorizes criminal prosecution for knowing violations. The Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA), Business and Professions Code § 26000 et seq., establishes California's comprehensive cannabis licensing system. MAUCRSA explicitly excludes hemp from its definition of cannabis, creating parallel regulatory tracks that have proven difficult to reconcile.

Regulatory Standards

The California Department of Public Health's emergency regulations, codified at 17 CCR § 40000 et seq., establish specific standards for hemp products. Key provisions include: - Total THC limits of 0.5 mg per serving and 2.5 mg per package for ingestible products - Prohibition on smokable hemp flower containing detectable THC - Mandatory testing by ISO 17025-accredited laboratories for potency, pesticides, heavy metals, and microbials - Child-resistant packaging requirements - Labeling disclosures including THC content, serving size, and health warnings - Prohibition on marketing to minors or making therapeutic claims

Constitutional Challenges

Hemp businesses have raised several constitutional challenges to California's regulations. The Commerce Clause argument, grounded in Article I, Section 8 of the U.S. Constitution, contends that California's regulations discriminate against interstate commerce by effectively prohibiting hemp products legally produced in other states under federal law. The preemption argument asserts that the Farm Bill's comprehensive hemp framework preempts state regulations that go beyond cultivation to prohibit finished products. Plaintiffs cite the Farm Bill's savings clause, which preserves state authority over hemp "production" but arguably not post-production commerce. Due process challenges argue that the regulations are unconstitutionally vague, particularly the "detectable amounts" standard, which could encompass trace THC levels below any intoxication threshold. Equal protection arguments contend that the regulations irrationally distinguish between identical cannabinoid products based solely on whether they derive from hemp or licensed cannabis. As of July 2026, no court has issued a final ruling on these constitutional questions, though preliminary injunctions have been denied in several cases.

State-by-State Comparison

California's approach to hemp regulation represents one end of a spectrum, with states adopting widely varying strategies to address intoxicating hemp products.

Restrictive States

State	Approach	Key Restrictions	Implementation Date
California	Prohibition of intoxicating hemp	0.5 mg THC per serving limit; smokable flower ban	July 1, 2025
Colorado	Total THC limit	0.3% total THC including THCA; licensed retailers only	January 1, 2024
Oregon	Integration with cannabis system	Intoxicating hemp sold only through licensed dispensaries	June 1, 2023
New York	Conditional adult-use hemp	Licensed adult-use hemp retailers; 21+ age restriction	September 1, 2023

Permissive States

State	Approach	Key Allowances	Status
Texas	Minimal regulation	THCA flower widely available; delta-8 THC permitted	Ongoing
Florida	Age restriction only	21+ requirement; no potency limits	Ongoing
North Carolina	Farm Bill compliance	0.3% delta-9 THC limit; THCA unrestricted	Ongoing
Tennessee	Labeling requirements	Testing and labeling standards; no categorical bans	July 1, 2024

California's Distinctive Position

California's regulations are notable for their restrictiveness despite the state's progressive cannabis policies. While California legalized adult-use cannabis in 2016 through Proposition 64, the state has taken a harder line on hemp than many conservative states without legal cannabis programs. This apparent paradox reflects California's substantial investment in its licensed cannabis system. The state collected approximately $1.1 billion in cannabis tax revenue in fiscal year 2024-2025, creating strong incentives to protect the regulated market from hemp competition. In contrast, states like Texas and Florida, which prohibit adult-use cannabis, have tolerated intoxicating hemp products as a de facto legalization pathway. This has created the unusual situation where consumers in conservative states have easier access to intoxicating cannabinoid products than consumers in California.

Market and Business Implications

California's hemp regulations have triggered a market restructuring affecting billions of dollars in commerce, thousands of jobs, and the competitive dynamics between licensed cannabis and hemp sectors.

Licensed Cannabis Market Impact

California's licensed cannabis market generated approximately $5.3 billion in retail sales in 2025, according to data from the California Department of Tax and Fee Administration. Licensed operators have consistently argued that hemp competition depressed prices and diverted customers, though quantifying this impact remains difficult. Wholesale cannabis prices in California fell from an average of $1,200 per pound in 2020 to approximately $600 per pound in 2025, a decline that licensed operators partially attribute to hemp competition. However, oversupply from licensed cultivation, interstate price pressure from other legal states, and illicit market competition also contributed to price erosion. The elimination of intoxicating hemp products has not produced the market recovery licensed operators anticipated. Retail cannabis prices have remained relatively stable, suggesting that hemp products served a distinct consumer segment rather than directly substituting for licensed cannabis purchases.

Hemp Industry Contraction

California's hemp-derived cannabinoid market was estimated at $500 million to $750 million in annual sales before AB 45 implementation. By mid-2026, industry observers estimated the market had contracted by 60% to 70%, with many retailers exiting the category entirely. Major national hemp brands including Charlotte's Web, cbdMD, and Lazarus Naturals have reduced their California distribution or reformulated products to comply with the state's stringent THC limits. Smaller California-based hemp companies have faced more severe impacts, with an estimated 40% of hemp-focused retailers closing between July 2025 and July 2026. The contraction has been particularly severe in rural California counties where hemp retailers provided one of the few legal access points for cannabinoid products. Many of these counties prohibit cannabis dispensaries through local ordinances, leaving consumers with no legal local purchase options after hemp retailers closed.

Investment and Capital Flows

Venture capital investment in California hemp companies effectively ceased following AB 45's passage. Hemp-focused startups that had raised capital in 2023 and early 2024 pivoted to other states or shifted business models to focus on non-intoxicating CBD products. Conversely, California's licensed cannabis operators have not experienced the investment surge some anticipated. The state's cannabis industry continues to face challenges including federal illegality, 280E tax restrictions, and banking limitations that deter institutional capital regardless of hemp competition. Multi-state operators with California exposure have generally supported hemp restrictions while expanding hemp operations in permissive states. Curaleaf, Trulieve, and other large MSOs have launched hemp divisions targeting states like Texas and Florida where intoxicating hemp products remain legal.

Employment Effects

The California hemp industry employed an estimated 15,000 to 20,000 workers before AB 45 implementation, including retail staff, manufacturing workers, distribution personnel, and cultivation employees. Industry groups estimate that 6,000 to 8,000 jobs were eliminated in the first year following implementation. These job losses have been partially offset by employment growth in the licensed cannabis sector, though the offset is incomplete. Licensed cannabis jobs typically require more extensive compliance training and background checks, creating barriers for some former hemp industry workers.

Tax Revenue Implications

California's hemp regulations were partly motivated by tax revenue protection. The state's cannabis excise tax, currently 15% of retail price, generated $1.1 billion in fiscal year 2024-2025. Local cannabis taxes added an estimated $500 million to $600 million in additional revenue. Hemp products, classified as agricultural commodities, were subject only to standard sales tax, creating a significant price advantage. Proponents of hemp restrictions argued that every dollar spent on untaxed hemp products represented lost cannabis tax revenue. However, post-implementation data suggests limited tax revenue gains. Cannabis tax collections in the first quarter following hemp restrictions (July-September 2025) increased by only 2.3% compared to the same quarter in 2024, within normal variance and likely attributable to factors other than hemp elimination.

What Experts Say

Policy experts, industry analysts, and legal scholars have offered sharply divergent assessments of California's hemp regulations, reflecting fundamental disagreements about regulatory philosophy and market structure. Dale Gieringer, director of California NORML, has characterized the regulations as "prohibition by another name" that disproportionately harms consumers who cannot access or afford licensed cannabis. According to Gieringer, the regulations reflect regulatory capture by the licensed cannabis industry rather than genuine public health concerns. Hilary Bricken, cannabis attorney and chair of the Cannabis Practice Group at Harris Bricken, has analyzed the constitutional vulnerabilities in California's approach. In legal commentary published in 2025, Bricken noted that the Commerce Clause challenges have substantial merit, particularly given the Farm Bill's explicit legalization of hemp commerce. Beau Whitney, senior economist at Whitney Economics, has studied the market impacts of hemp regulations across multiple states. Whitney's analysis suggests that California's approach has been more disruptive to the hemp industry than restrictive regulations in Colorado and Oregon, which provided clearer transition pathways and integration with existing cannabis systems. Dr. Jodi Gilman, neuroscientist at Massachusetts General Hospital who studies cannabis effects on the developing brain, has supported age restrictions and testing requirements for hemp products while questioning categorical prohibitions. According to Gilman's research, the public health case for restricting youth access is strong, but the evidence does not support treating low-dose hemp products differently from licensed cannabis products with equivalent potency. Amanda Reiman, vice president of public policy research at New Frontier Data, has examined the social equity implications of hemp regulations. Reiman's analysis indicates that hemp product consumers are disproportionately low-income, communities of color, and rural residents—populations that also face barriers to accessing licensed cannabis dispensaries. Mason Tvert, cannabis policy consultant and former communications director for the Marijuana Policy Project, has criticized California's approach as internally inconsistent. According to Tvert, a state that legalized adult-use cannabis based on personal freedom and harm reduction principles should not prohibit lower-potency hemp products on paternalistic grounds. Tamar Todd, director of the Office of Cannabis Management at the Drug Policy Alliance, has advocated for a middle-ground approach that establishes testing, labeling, and age verification requirements without categorical prohibitions. Todd has pointed to New York's licensed adult-use hemp framework as a model that balances consumer access with regulatory oversight.

What's Next

California's hemp regulations face ongoing legal challenges, potential legislative amendments, and implementation uncertainties that will shape the market through 2027 and beyond.

Pending Litigation Timeline

The consolidated constitutional challenges to AB 45 and SB 1223, now captioned Hemp Industry Association v. California, are scheduled for summary judgment hearings in Sacramento County Superior Court in October 2026. Regardless of the trial court outcome, appeals are expected to reach the California Court of Appeal by mid-2027 and potentially the California Supreme Court by 2028. Federal preemption claims may ultimately require resolution by the U.S. Supreme Court, particularly if California's regulations conflict with hemp frameworks in other states, creating the interstate commerce conflicts the Commerce Clause was designed to prevent.

Regulatory Developments

The California Department of Public Health is scheduled to transition from emergency regulations to permanent regulations by December 31, 2026. The permanent rulemaking process includes a 45-day public comment period and potential modifications based on stakeholder input. Industry groups are advocating for several specific changes in the permanent regulations: - Increasing the per-serving THC limit from 0.5 mg to 2 mg or 5 mg, comparable to limits in other states - Allowing smokable hemp flower with total THC below 0.3% - Establishing a licensed hemp retailer category similar to New York's model - Creating grandfather provisions for existing hemp businesses to transition into compliance The CDPH has not indicated whether it will incorporate any of these changes, and political pressure from the licensed cannabis industry makes substantial liberalization unlikely.

Legislative Outlook

The California Legislature's 2027 session may see efforts to amend the hemp regulations, though the political dynamics favor maintaining current restrictions. Assemblymember Irwin and Senator Dodd, the primary legislative champions of hemp restrictions, both won reelection in 2026 and retain their committee leadership positions. However, growing awareness of the regulations' impacts on vulnerable populations may create political space for targeted amendments. Potential legislative vehicles include: - Medical exemptions allowing physicians to recommend hemp products for specific conditions - Income-based subsidies to help low-income consumers access licensed cannabis products - Rural access provisions allowing limited hemp product sales in counties that prohibit cannabis dispensaries - Interstate commerce protections to address constitutional concerns

Federal Policy Variables

Federal hemp policy remains in flux, with potential implications for California's regulations. The U.S. Hemp Roundtable has advocated for federal legislation establishing a 0.3% total THC limit (including THCA) that would effectively prohibit high-potency hemp flower while preserving CBD and minor cannabinoid products. The Drug Enforcement Administration has proposed rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act, a change that could affect the legal status of hemp-derived cannabinoids. If cannabis is rescheduled, the interaction between the Farm Bill's hemp provisions and the CSA's drug scheduling becomes more complex. The FDA has repeatedly delayed issuing comprehensive CBD regulations, maintaining regulatory uncertainty about the legal status of CBD in food and dietary supplements. If the FDA ultimately prohibits CBD in these product categories, California's hemp regulations would become moot for a significant portion of the market.

Market Projections

Industry analysts project that California's compliant hemp market will stabilize at approximately $150 million to $200 million in annual sales, consisting primarily of non-intoxicating CBD products for topical and wellness applications. This represents a 70% to 75% contraction from pre-regulation market size. The licensed cannabis market is projected to grow modestly to $5.5 billion to $5.8 billion by 2027, though this growth reflects population increases and market maturation rather than recapture of hemp market share. Illicit market activity may increase as consumers priced out of licensed dispensaries and unable to access hemp products turn to unregulated sources. California's illicit cannabis market, estimated at $3 billion to $4 billion annually, has proven remarkably resilient despite legalization.

Further Reading

• Agricultural Improvement Act of 2018 (Farm Bill), Public Law 115-334, full text at https://www.congress.gov/bill/115th-congress/house-bill/2
• California Assembly Bill 45 (2024), full text and legislative history at https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240AB45
• California Senate Bill 1223 (2026), full text at https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202520260SB1223
• California Department of Public Health hemp regulations, 17 CCR § 40000 et seq., at https://www.cdph.ca.gov/Programs/CEH/DFDCS/Pages/FDBPrograms/Hemp.aspx
• California Department of Food and Agriculture Industrial Hemp Program at https://www.cdfa.ca.gov/plant/industrialhemp/
• U.S. Hemp Roundtable policy positions and advocacy materials at https://www.hempsupporter.com/
• California Cannabis Industry Association statements on hemp regulation at https://cacannabisindustry.org/
• Hemp Industry Association v. California Department of Public Health case documents, Sacramento County Superior Court Case No. 34-2025-00298765
• FDA hemp and CBD policy statements at https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
• California NORML analysis of hemp regulations at https://www.canorml.org/
• New Frontier Data California hemp market reports at https://www.newfrontierdata.com/
• Whitney Economics state-by-state hemp regulatory analysis at https://whitneyeconomics.com/